2014
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan N, Boyer JL, Herbst RS. A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer. Clinical Cancer Research 2014, 20: 3921-3930. PMID: 24893629, PMCID: PMC5369356, DOI: 10.1158/1078-0432.ccr-13-1762.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerClinical trialsNew clinical trialsEarly clinical trialsPathway-targeted therapiesTargeted therapyMechanism of activityNovel targetCancerDruggable targetsTherapyDisappointing resultsHuman cancersSmall-molecule screenFarnesyltransferase inhibitorsRAS gene productsNew RATrialsPharmaceutical companiesNumerous oncogenesNumerous studiesSynthetic lethality screenPathway
2013
Tyrosine-kinase inhibitors in oncology
Tsao A, Papadimitrakopoulou V, Herbst R. Tyrosine-kinase inhibitors in oncology. 2013, 872-883. DOI: 10.1017/cbo9781139046947.083.Peer-Reviewed Original ResearchHigh-throughput technologiesKey oncogenic pathwaysGenomic eraMechanistic targetComplexity of cancerOncogenic pathwaysMolecular perspectiveHuman cancersMolecular oncologyMolecular changesHuman malignanciesPathwayCancer tissuesCritical driverTyrosine kinase inhibitorsMalignant transformationNew discoveriesGenomicsDiscoveryGenesMutationsEnormous stridesNew drugsInhibitorsCancer
2011
Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets, Complementary/Innovative Treatment, and Therapeutic Modalities
Hong W, Herbst R. Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets, Complementary/Innovative Treatment, and Therapeutic Modalities. 2011 DOI: 10.21236/ada548594.Peer-Reviewed Original ResearchRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayLung cancerTherapeutic modalitiesNSCLC pathogenesisEGFR pathwayInnovative treatmentsMolecular targetsERK pathwaySignal transduction pathwaysImaging techniquesModalitiesPathwayTransduction pathwaysPeptide approachPatientsPathogenesisCancerReceptors
2010
BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)
Hong W, Herbst R, Kim E. BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination). 2010 DOI: 10.21236/ada542458.Peer-Reviewed Original ResearchIMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities). 2010 DOI: 10.21236/ada525846.Peer-Reviewed Original Research
2009
IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2009 DOI: 10.21236/ada504658.Peer-Reviewed Original Research
2008
To kill a tumor cell: the potential of proapoptotic receptor agonists
Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. Journal Of Clinical Investigation 2008, 118: 1979-1990. PMID: 18523647, PMCID: PMC2396896, DOI: 10.1172/jci34359.Peer-Reviewed Original ResearchConceptsProapoptotic receptor agonistsApo2L/TRAILReceptor agonistRecombinant human Apo2L/TRAILExtrinsic apoptosis pathwayPotential therapeutic interventionsNovel molecular biomarkersApoptosis pathwayAgonistic mAbConventional therapyPreclinical dataTherapeutic interventionsTumor cellsMolecular biomarkersAbnormal cellsLogical targetTherapyAgonistsCellsExciting opportunitiesTumorigenesisPatientsApoptosisPathwayIMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada486510.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptorsIMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities). 2008 DOI: 10.21236/ada483184.Peer-Reviewed Original ResearchMalignant pleural effusionRaf/MEK/ERK pathwayMEK/ERK pathwayRas/Raf/MEK/ERK pathwayAdvanced diseasePleural effusionLung cancerNSCLC pathogenesisMolecular therapyEGFR pathwayERK pathwayCD-ROM programSignal transduction pathwaysImaging techniquesPathwayTransduction pathwaysPeptide approachPulmonologistsEffusionPathogenesisTherapyCancerDiseasePreventionReceptorsMultitargeted Inhibitors in Lung Cancer: New Clinical Data
Bar J, Herbst RS, Onn A. Multitargeted Inhibitors in Lung Cancer: New Clinical Data. Clinical Lung Cancer 2008, 9: s92-s99. PMID: 19419930, DOI: 10.3816/clc.2008.s.014.Peer-Reviewed Original ResearchConceptsLung cancerManagement of patientsCell lung cancerOngoing clinical trialsNew clinical dataCombination of therapiesTreatment arsenalMultitargeted therapyClinical trialsNovel therapiesClinical dataNovel agentsRadiation therapyTraditional chemotherapyTherapyCancerClinical useMalignant growthMultitargeted inhibitorsTreatmentPathwayMajor pathwayChemotherapyPatientsAgents